Sage Therapeutics faces challenges with a 90% value drop but shows promise with Zurzuvae for postpartum depression. Click ...

Biogen's $7.22 per share buyout offer signals confidence in Sage's commercial potential and drug pipeline. Read why SAGE ...

Biogen's research organization recently went through an overhaul that company leaders say should allow the Cambridge drugmaker to increase the number of molecules that get into the clinic, and then, ...

Organon acquired regulatory and commercial rights in the United States for TOFIDENCE ™, a biosimilar to ACTEMRA ®, for intravenous infusion from Biogen. TOFIDENCE, the first approved ...

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA ...

Biogen has turned to M&A to offset its recent ... therapy dapirolizumab pegol as well as Sage Therapeutics-partnered antidepressant zuranolone, although a lack of commentary on the latter in ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

RNA therapeutics have existed since the late 90s but have only come into focus in the last few years. This renewed interest has largely been attributed to the success of messenger RNA (mRNA) vaccines ...

Biogen briefly moved its headquarters out to Weston, a town 30 minutes from Kendall Square, in 2010 before quickly announcing it would move back to Cambridge a year later.

Xero vs Sage: Best Accounting Software for 2025? Your email has been sent Here’s my comparison of Xero vs Sage and determine which software suits your business’ accounting and financial ...